APA (7th ed.) Citation

C, T., Q, D., S, C., C, V., & P, B. (2026). AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine (Adjuvanted RSVPreF3): Review of the First 2 Years of Post-Marketing Safety Surveillance. Drug safety. https://doi.org/10.1007/s40264-026-01698-y

Chicago Style (17th ed.) Citation

C, Tregunno, Deraedt Q, Cuadripani S, Verheust C, and Bryan P. "AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine (Adjuvanted RSVPreF3): Review of the First 2 Years of Post-Marketing Safety Surveillance." Drug Safety 2026. https://doi.org/10.1007/s40264-026-01698-y.

MLA (9th ed.) Citation

C, Tregunno, et al. "AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine (Adjuvanted RSVPreF3): Review of the First 2 Years of Post-Marketing Safety Surveillance." Drug Safety, 2026, https://doi.org/10.1007/s40264-026-01698-y.